Showing 7711-7720 of 8159 results for "".
- XOMA Finalizes Gevokizmab Phase III Clinical Program in Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20140428-xoma_finalizes_gevokizmab_phase_3_clinical_program_in_pyoderma__gangrenosum/2459254/Xoma Corporation finalized the plans for gevokizumab Phase III Program in Pyoderma Gangrenosum (PG). The Phase III Study will include two double-blind placebo-controlled clinical studies with 60 patients who have active PG. Paul Rubin, Senior Vice President,
- ALPHAEON Launches New Patient Financing Solutionhttps://practicaldermatology.com/news/20140425-alphaeon_launches_new_patient_financing_solution/2459256/ALPHAEON Corporation, a subsidiary of Strathspey Crown Holdings, LLC, launched ALPHAEON CREDIT, which the company describes as a new tool for patients seeking to finance self-pay lifestyle healthcare procedures through board-certified specialty physicians in dermatology, ophthalmology, plast
- Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lineshttps://practicaldermatology.com/news/20140421-revance_therapeutics_announces_positive_results_from_the_rt002_phase_12_study_in_glabellar_frown_lines/2459262/Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced positive data from its Phase 1/2 study of RT002 injectable botulinum toxin type A for the treatment of moderate to severe glabellar (frown) lines. RT002 is Revance's proprietary, injectable botulinum toxin investigational product that incorpo
- Foamix Gains Five Additional US Patentshttps://practicaldermatology.com/news/20140421-foamix_gains_five_additional_us_patents/2459263/The United States Patent and Trademark Office (USPTO) issued Foamix five new patents covering its technologies. Foamix, a specialty pharmaceutical company, focuses on developing and commercializing proprietary topical foams. The additional five patents raises Foamix's number to 25 United
- bioskin Continues US Expansion with Launch of New Websitehttps://practicaldermatology.com/news/20140417-bioskin_continues_us_expansion_with_launch_of_new_website/2459268/bioskin® follows expansion of its US office, spearheaded by AJ Acker, Executive Director of Global Regulatory and Clinical Affairs, with the launch of our a website www.bioskinCRO.com. The new layout was designed with ease of u
- Residents Provided with Online Education by ASDShttps://practicaldermatology.com/news/20140416-residents_provided_with_online_education_by_asds/2459270/Kyle M. Coleman, MD, has developed a dermatologic surgery educational series as part of the ASDS Future Leaders Network. The "Better Surgical Education" video series, focusing on dermatologic surgery topics and procedures, will provide additional education opportunities for residency programs.
- L'Oreal Partners with Celebrities for New Melanoma PSAhttps://practicaldermatology.com/news/20140416-loreal_partners_with_celebrities_for_new_melanoma_psa/2459271/L'Oréal is partnering with Melanoma Research Alliance (MRA) to launch the campaign "It's THAT Worth It™." Diane Keaton, skin cancer survivor will be featured urging women of all skin tones to use sunscreen. Other celebrities join Keaton in this campaign in print and broadcast PSAs
- SkinCeuticals Announces the Launch of its First US Flagship Locationhttps://practicaldermatology.com/news/20140414-skinceuticals_announces_the_launch_of_its_first_us_flagship_location/2459274/SkinCeuticals launched SkinCeuticals Advanced Clinical Spa with Manhattan Dermatology and Cosmetic Surgery, the first flagship location. An exclusive Integrated Skincare treatment menu has been created, featuring comprehensive offerings that range from clinical procedures to
- TetraLogic Acquires Shape Pharmaceuticals, Inc.https://practicaldermatology.com/news/20140407-tetralogic_acquires_shape_pharmaceuticals_inc/2459275/TetraLogic Pharmaceuticals Corporation has entered an agreement to acquire Shape Pharmaceuticals, a biotechnology company. Shape Pharmaceuticals is developing SHAPE, which is a tissue-targeted HDAC inhibitor in a topical gel formulation to treat stage IA-IIA Cutaneous T-Cell Lymphoma.
- Alma Lasers Hosts Special Programs at the 34th ASLMS Conference in Phoenixhttps://practicaldermatology.com/news/20140403-alma_lasers_hosts_special_programs_at_the_34th_aslms_conference_in_phoenix/2459279/The ASLMS, provider of laser, light-based, radio frequency and ultrasound technologies, invites guests to hear from leading experts. Michael Gold, of Gold Skin Care in Nashville, Tennessee, will moderate the night's discussion. Others include: Macrene Alexiades-Armenakas, MD, director a